Bioventus (BVS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Bioventus (BVS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 12.92% |
| 10 | Bioventus | 967.14 Mn | 937.68 Mn | 105.67 Mn | 290.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 290.48% |
| Mar 28, 2026 | 218.78% |
| Apr 1, 2023 | -18,460.85% |
| Dec 31, 2022 | -93,484.00% |
| Oct 1, 2022 | -1,868.40% |
| Jul 2, 2022 | 97.40% |
| Apr 2, 2022 | -101.63% |
| Dec 31, 2021 | -101.11% |
| Oct 2, 2021 | -128.49% |
| Jul 3, 2021 | -80.27% |
| Apr 3, 2021 | 133.91% |